Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain

British Journal of Haematology

Volumn 149, Issue 6, 2010, Pages 916-918

  Mangiacavalli, Silvia ^a   Corso, Alessandro ^a   De Amici, Mara ^a   Varettoni, Marzia ^a   Alfonsi, Enrico ^a   Lozza, Alessandro ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Bortezomib; Diabetes; Myeloma; Neuropathy

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; UNCLASSIFIED DRUG; VEL DEX;

CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG WITHDRAWAL; HUMAN; INFLAMMATION; LETTER; LYMPHOCYTE SUBPOPULATION; MACROPHAGE ACTIVATION; MULTIPLE MYELOMA; NERVE FIBER DEGENERATION; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEURALGIA; PROSPECTIVE STUDIES; PYRAZINES; TH2 CELLS;

EID: 77952704529     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08138.x     Document Type: Letter

References (8)

1. Argyriou, A., Iconomou, G. Kalofonos, H.P. (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593 1599.
2. Cameron, P. Cotter, M.A. (2008) Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Current Drug Targets, 9, 60 67.
3. Cata, J.P., Weng, H.R., Burton, A.W., Villarreal, H., Giralt, S. Dougherty, P.M. (2007) Quantitative sensory findings in patients with bortezomib-induced pain. The Journal of Pain, 8, 296 306.
4. Cavaletti, G., Gilardini, A., Canta, A., Rigamonti, L., Rodriguez-Menendez, V., Ceresa, C., Marmiroli, P., Bossi, M., Oggioni, N., D'Incalci, M. De Coster, R. (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Experimental Neurology, 204, 317 325.
5. Herder, C., Lankisch, M., Ziegler, D., Rathmann, W., Koenig, W., Illig, T., Doring, A., Thorand, B., Holle, R., Giani, G., Martin, S. Meisinger, C. (2009) Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care, 32, 680 682.
6. Horiuchi, I., Ochi, H., Murai, H., Osoegawa, M., Minohara, M., Furuya, H. Kira, J. (2001) Th2 shift in mononeuritis multiplex and increase of Th2 cells in chronic inflammatory demyelinating polyneuropathy: an intracellular cytokine analysis. Journal of the Neurological Sciences, 193, 49 52.
7. Meregalli, C., Canta, A., Carozzi, V.A., Chiorazzi, A., Oggioni, N., Gilardini, A., Ceresa, A., Arezza, F., Crippa, L., Marmiroli, P. Cavaletti, G. (2009) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. European Journal of Pain, doi:.
8. Ravaglia, S., Corso, A., Piccolo, G., Lozza, A., Alfonsi, E., Mangiacavalli, S., Varettoni, M., Zappasodi, P., Moglia, A., Lazzarino, M. Costa, A. (2008) Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clinical Neurophysiology, 119, 2507 2512.